TNDM Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -9.53% compared to Tandem Diabetes Care's net margin of 8.28%. Tandem Diabetes Care's return on equity of -47.23% beat Globus Medical's return on equity of 2.27%.

Tandem Diabetes Care has a consensus price target of --, signalling upside risk potential of 39.31%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.39%. Given that Tandem Diabetes Care has higher upside potential than Globus Medical, analysts believe Tandem Diabetes Care is more attractive than Globus Medical.

Tandem Diabetes Care has a beta of 1.324, which suggesting that the stock is 32.425% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $244M, which are smaller than Globus Medical quarterly revenues of $625.7M. Tandem Diabetes Care's net income of -$23.3M is lower than Globus Medical's net income of $51.8M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Globus Medical's PE ratio is 124.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 2.80x versus 4.60x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of -9.53% compared to Tandem Diabetes Care's net margin of 9.79%. Tandem Diabetes Care's return on equity of -47.23% beat Haemonetics's return on equity of 13.51%.

Tandem Diabetes Care has a consensus price target of --, signalling upside risk potential of 39.31%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 43.56%. Given that Haemonetics has higher upside potential than Tandem Diabetes Care, analysts believe Haemonetics is more attractive than Tandem Diabetes Care.

Tandem Diabetes Care has a beta of 1.324, which suggesting that the stock is 32.425% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $244M, which are smaller than Haemonetics quarterly revenues of $345.5M. Tandem Diabetes Care's net income of -$23.3M is lower than Haemonetics's net income of $33.8M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Haemonetics's PE ratio is 32.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 2.80x versus 2.92x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -9.53% compared to Tandem Diabetes Care's net margin of 1.94%. Tandem Diabetes Care's return on equity of -47.23% beat Masimo's return on equity of 5.75%.

Tandem Diabetes Care has a consensus price target of --, signalling upside risk potential of 39.31%. On the other hand Masimo has an analysts' consensus of $172.77 which suggests that it could grow by 3.14%. Given that Tandem Diabetes Care has higher upside potential than Masimo, analysts believe Tandem Diabetes Care is more attractive than Masimo.

Tandem Diabetes Care has a beta of 1.324, which suggesting that the stock is 32.425% more volatile than S&P 500. In comparison Masimo has a beta of 1.010, suggesting its more volatile than the S&P 500 by 1.04%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $244M, which are smaller than Masimo quarterly revenues of $504.6M. Tandem Diabetes Care's net income of -$23.3M is lower than Masimo's net income of $9.8M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Masimo's PE ratio is 115.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 2.80x versus 4.46x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -9.53% compared to Tandem Diabetes Care's net margin of 14.25%. Tandem Diabetes Care's return on equity of -47.23% beat Insulet's return on equity of 49.55%.

Tandem Diabetes Care has a consensus price target of --, signalling upside risk potential of 39.31%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 8.47%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Tandem Diabetes Care has a beta of 1.324, which suggesting that the stock is 32.425% more volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $244M, which are smaller than Insulet quarterly revenues of $543.9M. Tandem Diabetes Care's net income of -$23.3M is lower than Insulet's net income of $77.5M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Insulet's PE ratio is 45.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 2.80x versus 10.14x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.